TITLE

FDA Actions

PUB. DATE
February 2009
SOURCE
Travel Medicine Advisor;Feb2009 Supplement, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on actions taken by the U.S. Food and Drug Administration (FDA) on some pharmaceutical products. The agency is requiring a boxed warning on sodium phosphate bowel cleansing products to protect users from the risk of acute phosphate nephropathy. The FDA is also requiring warning on all anti-epileptic drugs due to risk of suicidal thoughts and behavior. The agency announced the approval of fenofibric acid for use with statin for the treatment of dyslipidemia.
ACCESSION #
36364696

 

Related Articles

  • FDA has updated labeling for antiepileptic drugs treating epilepsy.  // Drug Formulary Review;Jul2009, Vol. 25 Issue 7, p83 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) on the updated labeling for antiepileptic drugs used to treat epilepsy and psychiatric disorders. It cites that the FDA has conducted clinical studies of such drugs, which have shown consistent risk of suicidal...

  • FDA Boxed Warnings: How to Prescribe Drugs Safely. O'CONNOR, NINA R. // American Family Physician;2/1/2010, Vol. 81 Issue 3, p298 

    Boxed warnings, commonly referred to as "black box" warnings, are issued by the U.S. Food and Drug Administration and featured in the labeling of drugs associated with serious adverse reactions. These safety concerns are typically identified through the Adverse Event Reporting System and the...

  • FDA warns of potential intestinal issues with olmesartan medoxomil.  // Cardiology Today;Aug2013, Vol. 16 Issue 8, p18 

    The article reports that the U.S. Food and Drug Administration (FDA) approved the labeling changes to drugs containing olmesartan medoxomil, issuing a warning on its potential for intestinal problems.

  • FDA adds boxed warning to propylthiouracil. Kalwaitis, Katie; Southall, Jennifer // Endocrine Today;May2010, Vol. 8 Issue 5, p1 

    The article reports that the U.S. Food and Drug Administration (FDA) has added a boxed warning to propylthiouracil to include risks of severe liver injury and acute liver failure.

  • Boxed warning now required for antiphychotics for elderly with dementia.  // Primary Care Reports;Aug2008 Pharmacology Watch, p1 

    This article reports on a policy issued by the U.S. Food and Drug Administration in 2008 requiring a boxed warning for conventional antipsychotics. The policy concerns with an increased risk of mortality in elderly patients treated for dementia-elated psychosis. The policy expands the warning on...

  • Suicide Warnings for Antiepileptics.  // BioWorld Today;12/23/2008, Vol. 19 Issue 248, p6 

    The article highlights the order by the U.S. Food and Drug Administration (FDA) for manufacturers of antiepileptic drugs to add new warnings in product labeling that the medications increase the risk of suicidal thoughts and behaviors. Russell Katz, director of the Division of Neurology...

  • Warning About Byetta and Pancreatitis.  // Diabetes Health;Feb/Mar2008, Vol. 17 Issue 1, p32 

    The article reports that the U.S. Food and Drug Administration (FDA) has received complaints of acute pancreatitis among patients with type 2 diabetes who have been administered with Byetta. Out of the 30 patients, 27 had one or more risk factors for acute pancreatitis, such as gallstones or...

  • FDA's Graham Fires More Cardio Risk Bullets at Avandia. Young, Donna // BioWorld Today;6/30/2010, Vol. 21 Issue 125, p1 

    The article reports on the insistence of David Graham, associate director for science and medicine at the U.S. Food and Drug Administration's (FDA) Office of Surveillance and Epidemiology, to remove pharmaceutical company GlaxoSmithKline PLC's (GSK) Type II diabetes drug Avandia from the U.S....

  • FDA propose drug label changes for use in pregnancy.  // Reactions Weekly;6/7/2008, Issue 1205, p1 

    The article reports on changes to prescription drug labelling proposed by the U.S. Food and Drug Administration (FDA) to better inform patients of the risks and benefits of drugs that are used during pregnancy and breastfeeding. The changes are expected to help healthcare professionals give more...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics